[ad_1]
SHANGHAI 1 August 2018 / PRNewswire / – The [1] August 2018 Beijing time, I-Mab Biopharma ("I-Mab"), Shanghai Focused biotechnology company ed on Innovative Biologics in Oncology and Autoimmune Disease announced the appointment of Jielun Zhu as Chief Financial Officer (CFO). Mr. Zhu will report directly to Dr. Jingwu Zang President and CEO of I-Mab. Mr. Zhu has over 15 years of experience in investment banking and strategic consulting for global and regional healthcare clients. Jielun Zhu, MBA, CFO at I-Mab "/>
Jielun Zhu, MBA, CFO at I-Mab
" We are extremely happy to have Jielun joi n I-Mab, his expertise and experience in the financial management of health care. This is a vital addition to the senior management of I-Mab, "said Dr. Zang. "Jielun's entry comes at a critical time when our business is becoming more global and requires a solid financial strategy and business partnerships," adds Dr. Zang.
Immediately prior to joining I-Mab, Mr. Zhu was General Manager and Asia Head of Healthcare Investment Banking and Capital Markets in Hong Kong for Jefferies Group LLC. At Jefferies, he has led numerous strategic IPOs, mergers and acquisitions and other strategic transactions for biotechnology and other healthcare clients in the region. Greater China and beyond. Prior to Jefferies, he worked for Deutsche Bank in his office Hong Kong as a senior member of the Healthcare Coverage Team and for UBS AG in Hong Kong before. Previously, Mr. Zhu was a strategy consultant at Boston serving clients of the pharmaceutical and biotechnology industries in the United States.
Zhu earned his MBA from the Harvard Business School with Honors and B.A. with Honors from Wesleyan University. He also holds a CFA charter.
"I firmly believe that I-Mab is one of the most innovative companies that focuses on the development of first-rate and first-rate biological products in oncology and autoimmune diseases in patients.] China and around the world, "said Zhu. "The company has many globally competitive assets in its portfolio China and its global portfolio that are undergoing rapid development." Dr. Zang has successfully built a world-class team and I am looking forward to joining this team. […]
In June 2018 I-Mab successfully completed US $ 220 million financing which is the largest 39; one of the largest Financing C in China biopharmaceutical industry, following its financing of B series US $ 150 million in 2017. The company recently announced a US $ 100 million About I-Mab:
Facility through a merger between Third Venture Biotech and Tasgen Bio, followed by a Series B financing of USD 150 million in 2017, I-Mab quickly built a highly experienced team with world-class R & D capabilities. On 29 June 2018 I-Mab announced that he had successfully raised US $ 220 million in Series C financing with a group of well-known investors by Hony Capital, representing one of the largest ever ever rising C series by an innovative biotechnology company in China .
I-Mab focuses on the discovery and development of first-class and first-class biological products in the areas of immunity. oncology and immuno-inflammation. The company has already initiated a Phase 2 clinical trial and is ready to submit multiple IND applications for additional clinical trials in China and the US, including Phase 2 studies. and 3. www.i-mabbiopharma.com
Contact: [email protected] [email protected]
View original content with Multimedia: http: //www.prnewswire.com/news-releases/i-mab-biopharma-announces-new-cofo-300689393.html
